BIXT supply chain intelligence for Bioxytran, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Bioxytran, Inc. (BIXT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PHARMALECTIN-BVI-INC | PHARMALECTIN-BVI-INC | 85% | The Company holds a License Agreement (the “License” or “Agreement”) for a medical device (license obtained in 2019) with an affiliated company in which Company officers hold a majority interest. |
| PHARMALECTIN-INC | PHARMALECTIN-INC | 85% | The Company holds a License Agreement (the “License” or “Agreement”) for a medical device (license obtained in 2019) with an affiliated company in which Company officers hold a majority interest. |
| PHARMALECTIN-INDIA-PVT-LTD | PHARMALECTIN-INDIA-PVT-LTD | 85% | The Company holds a License Agreement (the “License” or “Agreement”) for a medical device (license obtained in 2019) with an affiliated company in which Company officers hold a majority interest. |
| AUCTUS-FUND-LLC | AUCTUS-FUND-LLC | 80% | 10.53 Amendment #1 to Securities Purchase Agreement between Auctus Fund LLC and Bioxytran, Inc., dated February 25, 2019 |
| LENDER | LENDER | 80% | 10.82 Securities Purchase Agreement between Bioxytran, Inc. and Lender, dated March 15, 2024 |
| POWER-UP-LENDING-GROUP-LLC | POWER-UP-LENDING-GROUP-LLC | 80% | 10.53 Amendment #1 to Securities Purchase Agreement between Auctus Fund LLC and Bioxytran, Inc., dated February 25, 2019 |
| RESOURCES-UNLIMITED-NW-LLC | RESOURCES-UNLIMITED-NW-LLC | 80% | 10.23 Investor Relations Agreement between Bioxytran, Inc. and Resources Unlimited NW LLC. dated April 22, 2019. |
| TRITON-FUNDS-LP | TRITON-FUNDS-LP | 80% | 10.76 Form of Closing Agreement with TRITON FUNDS LP, dated June 8, 2023 |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| KHOURY-MEDICAL-LTD | KHOURY-MEDICAL-LTD | 92% | Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR® Dietary Supplement |
| PHARMALECTIN-INC | PHARMALECTIN-INC | 90% | 10.59 License Agreement between Bioxytran, Inc. and Pharmalectin, Inc. dated May 5, 2020 |
| MDX-LIFESCIENCES-INC | MDX-LIFESCIENCES-INC | 80% | 10.22 License Agreement between Bioxytran, Inc. and MDX Lifesciences, Inc. dated April 4, 2019. |
| NDPD-PHARMA-INC | NDPD-PHARMA-INC | 80% | 10.60 License Agreement between Pharmalectin, Inc. and NDPD Pharma, Inc. dated May 2, 2021 |
| PHARMALECTIN-PARTNERS-LLC | PHARMALECTIN-PARTNERS-LLC | 80% | 10.57 Joint Venture Agreement between Bioxytran and Pharmalectin Partners, LLC, dated November 15, 2020. |
| BVI-BUSINESS-CORPORATION | BVI-BUSINESS-CORPORATION | 62% | . On October 25, 2024, the Company acquired 100 % of NDPD’s shares of Common Stock, the beneficial ownership of which included Company officers. As at March 31, 2026, there are 15,000,000 shares of C… |
| INDIAN-BUSINESS-CORPORATION | INDIAN-BUSINESS-CORPORATION | 62% | . On October 25, 2024, the Company acquired 100 % of NDPD’s shares of Common Stock from affiliates, the beneficial ownership of which included the Company officers. As at December 31, 2025, there are… |
| PHARMALECTIN-INDIA-PVT-LTD | PHARMALECTIN-INDIA-PVT-LTD | 62% | . On October 25, 2024, the Company acquired 100 % of NDPD’s shares of Common Stock from affiliates, the beneficial ownership of which included the Company officers. As at December 31, 2025, there are… |
| WALLACHBETH-CAPITAL-LLC | WALLACHBETH-CAPITAL-LLC | 62% | . The note has been in default since March 1, 2025. F- 15 At December 31, 2025, and 2024, the outstanding convertible notes were as follows: SCHEDULE OF OUTSTANDING CONVERTIBLE NOTES Name Principal d… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| BIXT-DEBT | Debt stack $48,070 | 90% | Market cache reports total debt of $48,070. |
| BIXT-DEBT-8215 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| BIXT-DEBT-8214 | Warrants outstanding: 15383334 | 90% | xbrl warrant detail from xbrl 2026-03-31. |